Please ensure Javascript is enabled for purposes of website accessibility

How Will Biden's Executive Orders Affect Your Healthcare Stocks?

By Brian Orelli, PhD - Feb 8, 2021 at 10:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The decisions could have both short- and long-term implications.

In this video from Motley Fool Live, recorded on Jan. 25, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss how the executive orders from President Joe Biden will affect healthcare investors. One of the executive orders could be a boon to COVID-19 testing companies, while the decision on the next commissioner of the Food and Drug Administration (FDA) could have an effect on the entire industry.

Corinne Cardina: What else do we know about President Biden's strategy to deal with the pandemic? Of course, he is going to be working hard with Congress to advance a significant legislative solution. But in the meantime, he has signed a lot of executive orders. Are there any that are relevant to healthcare investors?

Brian Orelli: I don't think this is an executive order, but Janet Woodcock is going to be the acting FDA director. She's been at the agency for decades. She's a career person. She's never held the FDA director position full-time and it's not quite clear where she's going to be the full-time FDA director, but she's definitely been a friend to the industry. I'm not necessarily a pushover, but somebody who wants to work with companies to get drugs approved -- so sort of a unified goal. She's probably most famous for stepping in and overriding the lower level FDA officials on the Sarepta Therapeutics (SRPT 3.52%), their first Duchenne's muscular dystrophy drug.

Biden is stopping the exit from the World Health Organization, WHO. I don't know how much of an effect that's going to have on companies. It's probably indirect, maybe better access to data that WHO generates, especially for surveillance during the next pandemic.

He's going to work on healthcare supplies, ramping up healthcare supplies through the Defense Production Act. There's potential for companies to get contracts there. But if you believe in capitalism, companies would already be doing this if there was a market for them to make money, so while they might get contracts, the margins might not be very high if they're forced to do it through the Defense Production Act.

Then he's going to work on a federal board to increase testing efforts that could definitely benefit test makers like Quidel (QDEL 0.62%) and Fulgent Genetics (FLGT 2.78%). It could also help the companies that run the tests, I'm thinking of Laboratory Corp. of America (LH 1.11%) and Quest Diagnostics (DGX 0.44%).

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$70.90 (3.52%) $2.41
Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$141.65 (0.44%) $0.62
Quidel Corporation Stock Quote
Quidel Corporation
QDEL
$99.60 (0.62%) $0.61
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
LH
$250.15 (1.11%) $2.75
Fulgent Genetics, Inc. Stock Quote
Fulgent Genetics, Inc.
FLGT
$55.90 (2.78%) $1.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.